Evenity (Romosozumab) Global Regulatory Status: What Women Need to Know

What Is Romosozumab and Who Approved It?

Romosozumab is a monoclonal antibody that inhibits sclerostin, a protein made by osteocytes that normally slows new bone formation. By blocking sclerostin, the drug simultaneously increases bone formation and modestly decreases bone resorption, a dual mechanism that distinguishes it from every bisphosphonate and denosumab on the market. The brand name in the United States, Canada, and several other markets is Evenity. The biological qualifier added by the FDA is romosozumab-aqqg.

The FDA granted approval on April 9, 2019, under New Drug Application 761062, for the treatment of osteoporosis in postmenopausal women at high risk of fracture, defined as a history of osteoporotic fracture, multiple risk factors for fracture, or failure or intolerance of other available osteoporosis therapy.

Every approval worldwide has been limited to postmenopausal women. No regulatory agency has approved romosozumab for men, premenopausal women, or adolescents.

How the Mechanism Sets It Apart from Other Osteoporosis Drugs

Most osteoporosis drugs work by slowing bone breakdown. Bisphosphonates (alendronate, risedronate, zoledronic acid) and denosumab are anti-resorptive agents. Teriparatide and abaloparatide are anabolic agents that stimulate formation but also raise resorption to some degree. Romosozumab is the only currently approved drug that increases bone formation markers while simultaneously suppressing bone resorption markers, a profile sometimes called "uncoupled" bone metabolism. This is relevant to women in early post-menopause who have lost substantial bone mass quickly, because they may benefit more from a drug that rebuilds bone rather than simply slowing further loss.

The Global Approval Timeline

Romosozumab was reviewed and approved across multiple jurisdictions in a narrow window:

| Jurisdiction | Agency | Approval Date | |---|---|---| | Japan | PMDA | March 2019 | | United States | FDA | April 9, 2019 | | European Union | EMA | September 2019 | | Canada | Health Canada | August 2019 | | Australia | TGA | 2019 |

The Japanese approval came first, partly because Amgen and UCB ran a dedicated Japanese bridging study (FRAME-J) in addition to the global FRAME trial.

The FDA Label: What It Actually Says

The FDA prescribing information for Evenity is specific about dose, duration, indication, and contraindications.

Approved Dose and Duration

The approved dose is 210 mg administered subcutaneously once monthly for 12 months, delivered as two consecutive 105 mg injections at two separate injection sites during the same visit. Treatment is 12 months only. The label states that the anabolic window closes after 12 months, meaning bone formation markers return to baseline even if the drug is continued. After completing the 12-month course, patients should transition to an anti-resorptive agent to maintain the bone density gains.

The Boxed Warning: Cardiovascular Risk

The most consequential label section is the boxed warning, the FDA's strongest safety alert. The label states that romosozumab may increase the risk of myocardial infarction, stroke, and cardiovascular death. The drug should not be started in patients who have had a heart attack or stroke within the preceding year.

This warning emerged from the ARCH trial, which was the head-to-head comparison of romosozumab followed by alendronate versus alendronate alone in postmenopausal women with osteoporosis. In ARCH (published in the New England Journal of Medicine in 2017), the romosozumab-then-alendronate group showed a significant reduction in new vertebral fractures (48% relative risk reduction) and hip fractures (38% relative risk reduction) compared with alendronate alone. However, serious cardiovascular events occurred in 2.5% of women in the romosozumab group versus 1.9% in the alendronate group, a difference that reached statistical significance. That imbalance drove the boxed warning.

The FRAME trial, the placebo-controlled study, did not show the same cardiovascular signal, which suggests the comparison in ARCH may partly reflect alendronate's protective effect on cardiovascular events rather than pure harm from romosozumab. The FDA reviewed both datasets and concluded a boxed warning was warranted regardless.

Contraindications in the FDA Label

The label lists the following contraindications:

• Hypocalcemia (must be corrected before starting treatment)
• History of myocardial infarction or stroke within the previous 12 months
• Known hypersensitivity to romosozumab or any excipient

What the Label Says About Monitoring

Before each dose, clinicians should assess serum calcium. Hypocalcemia occurred in patients in clinical trials and is more likely in women with vitamin D deficiency. Adequate calcium and vitamin D supplementation is required during treatment. The label specifies that patients should receive at least 1,000 mg of calcium and 800 IU of vitamin D daily during the 12-month course.

The EMA Approval and the European Perspective

The European Medicines Agency authorized Evenity in September 2019 through the centralized procedure. The EMA's European Public Assessment Report (EPAR) reached similar conclusions to the FDA but framed the cardiovascular risk slightly differently. The EMA considered the cardiovascular imbalance seen in ARCH to be a class effect concern and recommended that prescribers perform a cardiovascular risk assessment before initiating treatment. The EU label does not restrict the drug to women without prior cardiovascular disease in the same absolute terms as the FDA, but it does require a benefit-risk discussion with patients who have established cardiovascular disease.

The EMA's Committee for Medicinal Products for Human Use (CHMP) noted that the benefit of romosozumab in very high-risk fracture populations, particularly those with prior vertebral fractures, likely outweighs the cardiovascular risk for most postmenopausal women who do not have recent acute cardiovascular events. This reflects the same evidence-based trade-off clinicians face in everyday practice.

Pregnancy, Lactation, and Contraception: Required Reading

Romosozumab is contraindicated in pregnancy. This is not a relative contraindication. The drug's mechanism involves sclerostin inhibition, and sclerostin plays a role in fetal skeletal development. Animal studies showed fetal harm at doses that produced exposures comparable to human therapeutic exposure.

Pregnancy Category and Human Data

The FDA label assigns romosozumab to the category of drugs where animal reproduction studies have shown adverse fetal effects and there are no adequate, well-controlled studies in humans. Under the current Pregnancy and Lactation Labeling Rule (PLLR), the label states that available animal data show fetal harm and that use in pregnancy is not recommended. No human pregnancy exposure data exist from clinical trials because the drug was studied exclusively in postmenopausal women.

Life-Stage Context: Why This Matters

Because the approved indication is postmenopausal osteoporosis, the pregnancy contraindication is rarely clinically relevant in the typical patient. A 68-year-old postmenopausal woman with a prior vertebral fracture does not need a pregnancy test before starting romosozumab. However, a smaller subset of women may warrant consideration:

• Women with premature ovarian insufficiency (POI) who have been incorrectly categorized as postmenopausal but who may have residual fertility
• Women in perimenopause who are still ovulating irregularly and who might be considered for off-label use (which no guideline currently supports)
• Women who are candidates for oocyte donation or fertility preservation procedures after a breast cancer diagnosis where osteoporosis is a treatment complication (romosozumab would not be appropriate here)

For these edge cases, pregnancy status should be confirmed before any consideration of the drug, even though off-label use in premenopausal women is not supported by guideline evidence.

Lactation

The label states that there are no data on romosozumab in human milk, the effects on the breastfed infant, or the effects on milk production. Given that the drug is approved only in postmenopausal women, breastfeeding is not expected to be relevant in the clinical population. If a postmenopausal woman is somehow nursing (for example, induced lactation in a grandparent scenario, which is exceedingly rare), she should not use romosozumab given the complete absence of safety data in this context.

Contraception Requirement

Because postmenopausal women by definition are no longer at risk of pregnancy, the label does not include a formal contraception requirement. However, any clinician considering romosozumab in a perimenopausal or premenopausal woman outside the approved indication must confirm the patient uses reliable contraception for the duration of the 12-month treatment course.

How the Regulatory Status Affects Real Clinical Decisions

A practical framework for thinking about romosozumab regulatory approvals and clinical fit across life stages:

Postmenopausal women (the approved population). The drug is FDA-approved, EMA-authorized, and guideline-supported for women with a high fracture risk. The American Association of Clinical Endocrinologists (AACE) 2020 osteoporosis guidelines recommend anabolic therapy, including romosozumab, as first-line treatment in women at very high fracture risk, defined as a prior fragility fracture or T-score below negative 3.0. The Endocrine Society's 2019 pharmacological management guideline similarly endorses anabolic therapy first in severely osteoporotic postmenopausal women.

Early post-menopause (age 45 to 55). Women in early post-menopause who have rapid bone loss, particularly those who had surgical menopause or early natural menopause, may have T-scores that qualify for romosozumab even if they are relatively young. The drug has been approved for postmenopausal women without an age floor, so a 46-year-old with surgical menopause and a T-score of negative 2.8 with a prior fracture is within the approved label. Cardiovascular risk assessment is especially important in younger postmenopausal women who may have modifiable cardiovascular risk factors.

Perimenopause. There are no clinical trial data and no regulatory approval for use in perimenopausal women. Hormone therapy remains the preferred bone-protective intervention during perimenopause when bone loss is accelerating, per The Menopause Society's 2023 position statement on hormone therapy.

Premenopausal women. Off-label use is not guideline-supported. Bisphosphonates and denosumab also carry significant concerns in premenopausal women, and the evidence base for any of these drugs in that population is thin. For premenopausal women with osteoporosis due to conditions like PCOS-related amenorrhea, anorexia nervosa, or glucocorticoid use, the preferred approach is treating the underlying cause.

Cardiovascular Safety: Digging Into the Evidence

The cardiovascular signal in ARCH remains one of the most debated topics in osteoporosis pharmacology. Here is what the evidence actually shows.

ARCH in Detail

ARCH enrolled 4,093 postmenopausal women with osteoporosis and at least one vertebral fracture. Women were randomly assigned to receive romosozumab 210 mg monthly for 12 months followed by alendronate 70 mg weekly, or alendronate alone for the entire study period. The primary endpoint was new vertebral fracture at 24 months.

At 24 months, new vertebral fractures occurred in 6.2% of the alendronate-only group versus 3.3% of the romosozumab-then-alendronate group, a 48% relative risk reduction. Clinical fractures were reduced by 27% and hip fractures by 38%. These are substantial reductions. The cardiovascular event rate was the trade-off: serious cardiovascular adverse events in year one were 2.5% with romosozumab versus 1.9% with alendronate, and this difference persisted through 24 months.

FRAME in Detail

The FRAME trial enrolled 7,180 postmenopausal women with osteoporosis and compared romosozumab versus placebo for 12 months, followed by denosumab in both groups for 12 more months. The placebo-controlled data did not show a statistically significant cardiovascular imbalance. New vertebral fractures were reduced by 73% at 12 months with romosozumab versus placebo.

The divergence between ARCH and FRAME cardiovascular findings is most likely explained by alendronate's known cardioprotective properties in high-risk populations, which made the control arm healthier from a cardiovascular standpoint and made any cardiovascular signal in the romosozumab arm more apparent by comparison. The FDA's Sentinel program, which conducts post-market surveillance using real-world claims data, continues to monitor romosozumab cardiovascular outcomes in the approved postmenopausal population.

What This Means for Women with Cardiovascular Risk Factors

The boxed warning is not a blanket prohibition for all women with any cardiovascular history. A 72-year-old woman with well-controlled hypertension and a prior hip fracture, who has never had a heart attack or stroke, is not excluded by the label. The contraindication applies specifically to women who have had a myocardial infarction or stroke within the past 12 months. Women with established coronary artery disease or a remote history of cardiovascular events should have a thorough benefit-risk discussion with their prescribing clinician and, when warranted, their cardiologist.

Female-Relevant Conditions and Romosozumab

PCOS and Bone Health

Women with PCOS often have complex bone metabolism profiles. Insulin resistance and elevated androgens may partially protect bone density, but PCOS-related menstrual irregularity and low estrogen periods during reproductive years can reduce peak bone mass. Studies in women with PCOS have shown variable bone density outcomes. Romosozumab is not studied or approved in this population, and most women with PCOS are premenopausal, placing them outside the approved label. This is a genuine evidence gap.

Breast Cancer Treatment-Related Bone Loss

Women receiving aromatase inhibitors for breast cancer face accelerated bone loss, with annual BMD losses of 2 to 3% reported in studies of aromatase inhibitor therapy. Romosozumab is not approved for this indication, and its use in women with a history of hormone-receptor-positive breast cancer raises theoretical concerns because sclerostin inhibition may affect signaling pathways relevant to tumor biology. Bisphosphonates and denosumab remain the standard of care for aromatase inhibitor-induced bone loss. Women in this situation should not receive romosozumab outside a clinical trial.

Glucocorticoid-Induced Osteoporosis

Women with autoimmune conditions (lupus, rheumatoid arthritis, inflammatory bowel disease) frequently require long-term glucocorticoid therapy, which is one of the most common causes of secondary osteoporosis in women of all ages. The 2017 American College of Rheumatology (ACR) guidelines on glucocorticoid-induced osteoporosis recommend anabolic therapy in high-risk patients, and romosozumab is among the options. The FDA label does not restrict the drug to idiopathic postmenopausal osteoporosis. Postmenopausal women with glucocorticoid-induced osteoporosis who meet the fracture risk criteria in the label are within the approved indication.

Post-Market Surveillance and Real-World Data

Since April 2019, romosozumab has accumulated real-world use data. The FDA's Sentinel system continues to monitor for cardiovascular events, hypocalcemia, and hypersensitivity reactions. The most consistent real-world findings confirm the label-identified risks:

• Hypocalcemia, particularly in women with low vitamin D at baseline, remains the most common laboratory adverse event
• Injection-site reactions occur in approximately 10 to 15% of patients across trial data
• Osteonecrosis of the jaw and atypical femoral fractures, which are associated with long-term bisphosphonate use, have been reported rarely with romosozumab but are not considered a primary signal given the 12-month treatment duration

The FDA Adverse Event Reporting System (FAERS) continues to receive spontaneous reports of cardiovascular events, consistent with the boxed warning and the known patient population's background cardiovascular risk.

Who Is Right for Romosozumab, and Who Is Not

Women Who Are Likely Good Candidates

• Postmenopausal women with a prior vertebral or hip fracture (very high fracture risk)
• Postmenopausal women with a T-score at or below negative 2.5 who have had a fracture on another osteoporosis drug
• Postmenopausal women with multiple clinical fracture risk factors and a T-score below negative 3.0 who cannot tolerate bisphosphonates
• Women with rapid post-menopausal bone loss who need substantial bone mass gain, not just slowing of loss

Women Who Should Not Use Romosozumab

• Women who have had a heart attack or stroke in the past 12 months (boxed warning contraindication)
• Pregnant women or women planning pregnancy (contraindicated)
• Women with uncorrected hypocalcemia
• Premenopausal women (no approval, no guideline support, no meaningful safety data)
• Women with a history of hypersensitivity to romosozumab or its components

The Sequential Therapy Question

A point that many women and even some prescribers misunderstand: romosozumab must be followed by an anti-resorptive agent. The ARCH data show that the fracture risk reduction observed with romosozumab is sustained and even extended when alendronate is used afterward. Without a follow-on drug, bone density gains are largely lost within 12 months of stopping romosozumab. The label explicitly states that transition to anti-resorptive therapy is recommended after completing the 12-month romosozumab course.

Honest Assessment of the Evidence Gap

Women have long been underrepresented in cardiovascular and metabolic drug trials, but romosozumab is one of the few osteoporosis drugs studied exclusively in women, simply because the approved indication is specific to postmenopausal women. The fracture efficacy data from FRAME and ARCH are derived entirely from female subjects, which is a strength for women's-health evidence.

The genuine evidence gaps are in subpopulations. There are no romosozumab trial data in:

• Women younger than 45 with osteoporosis
• Premenopausal women of any age
• Women with concurrent hormone therapy (most trial participants were not on HT)
• Women from populations underrepresented in global trials (FRAME and ARCH enrolled predominantly White and Asian women)
• Women with a prior cardiovascular event who still have high fracture risk (these women were largely excluded from trials, yet they exist in clinical practice)

As WomanRx editorial board member Dr. Elena Vasquez notes: "The cardiovascular exclusion criteria in ARCH and FRAME mean we have almost no controlled data on romosozumab in the postmenopausal women who may face the sharpest trade-off between fracture risk and cardiac risk. These are exactly the women who need individualized clinical judgment, not a blanket rule from a trial that never enrolled them."

This gap is real. Clinicians managing postmenopausal women with both high fracture risk and established cardiovascular disease are making decisions based on extrapolation and registry data, not randomized trial evidence. That honesty matters when you are deciding whether to start a drug with a boxed warning.